Compare Abeona Therapeutics Inc (ABEO) vs Main Street Capital Corporation (MAIN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Main Street Capital Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while Main Street Capital Corporation trades at $51.31 (market cap $4.87B). The key difference: Main Street Capital Corporation is far larger — about 13× Abeona Therapeutics Inc's market cap, and Main Street Capital Corporation pays a 8.36% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MAIN | |
|---|---|---|
Market Cap | $373.32M | $4.87B |
Sector | Health | Financials |
52-Week High | $7.23 | $67.54 |
52-Week Low | $4.17 | $49.63 |
Enterprise Value | $228.22M | — |
Dividend Yield | — | 8.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Main Street Capital (MAIN) trades at $52.41, up 0.87% on the day, with a bullish technical signal and strong support near $52. The company reported a net income margin of 81.08% for 2025, though revenue declined slightly to $592 million. Recent corporate actions include a credit facility amendment extending maturity to 2031 and consistent dividend payments, highlighting its income-focused appeal.
Outlook remains mixed; the stock offers a high yield and stable dividends, but earnings misses and a high RSI suggest near-term caution. Analyst consensus is a Hold with a $57.75 price target, indicating modest upside potential amid execution risks and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →
